ArticleArteriosclerosis, thrombosis, and vascular biology2014
Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk.
Open access · bronzeAbstract read
In one paragraph
Article in Arteriosclerosis, thrombosis, and vascular biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 77 citations in OpenAlex.
- The role of blood CXCL12 level in prognosis of coronary artery disease: A meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Lack of an Association between the SDF-1 rs1801157 Polymorphism and Coronary Heart Disease: A Meta-Analysis.Scientific reports · 2015Pooled it
- Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride.Journal of diabetes investigation · 2017Trial
- Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.Cardiovascular diabetology · 2017Trial
- Mothers against decapentaplegic homolog 4 as a proteomic hub in vascular remodeling and residual cardiovascular risk.World journal of cardiology · 2026Article
- Gene Therapy for Heart Failure.Journal of cardiovascular translational research · 2026Review
- The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.Journal of the American College of Cardiology · 2025Review
- Unveiling causal relationships between addiction phenotypes and inflammatory cytokines: insights from bidirectional mendelian randomization and bibliometric analysis.European archives of psychiatry and clinical neuroscience · 2025Article
- Addressing Post-Acute COVID-19 Syndrome in Cancer Patients, from Visceral Obesity and Myosteatosis to Systemic Inflammation: Implications in Cardio-Onco-Metabolism.Biomedicines · 2024Review
- Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention.Cardiovascular diabetology · 2024Article
- Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.Bioengineering (Basel, Switzerland) · 2024Review
- The Heart of the Matter: Immune Checkpoint Inhibitors and Immune-Related Adverse Events on the Cardiovascular System.Cancers · 2023Review
- Decreased Serum Stromal Cell-Derived Factor-1 in Patients with Familial Hypercholesterolemia and Its Strong Correlation with Lipoprotein Subfractions.International journal of molecular sciences · 2023Article
- TFRC in cardiomyocytes promotes macrophage infiltration and activation during the process of heart failure through regulating Ccl2 expression mediated by hypoxia inducible factor-1α.Immunity, inflammation and disease · 2023Article
- Distinct Inflammatory Milieu in Patients With Right Heart Failure.Circulation. Heart failure · 2023Article
- Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes.International journal of molecular sciences · 2023Review
- Mental Stress-Induced Change in Plasma Stromal Cell-Derived Factor-1 and Adverse Cardiovascular Outcomes: A Cohort Study.CJC open · 2023Article
- Cardiovascular disease related circulating biomarkers and cancer incidence and mortality: is there an association?Cardiovascular research · 2022Article
- A finger in every pie - The versatility of chemokines.Biomedical journal · 2022Article
- Macrophage-Specific IGF-1 Overexpression Reduces CXCL12 Chemokine Levels and Suppresses Atherosclerotic Burden in Apoe-Deficient Mice.Arteriosclerosis, thrombosis, and vascular biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Subha SubramanianFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Chunyu LiuFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Abraham AvivFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Jennifer E HoFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Paul CourchesneFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Pieter MuntendamFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Martin G LarsonFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Susan ChengFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Thomas J WangFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Nehal N MehtaFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.).
Daniel LevyFrom the Framingham Heart Study, MA (S.S., C.L., J.E.H., P.C., M.G.L., S.C., D. L.); Population Sciences Branch (S.S., C.L., P.C., D.L.) and Division of Intramural Research (S.S., C.L., P.C., N.N.M., D. L.), National Heart, Lung, and Blood Institute, Bethesda, MD; The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, NJ (A.A.); Cardiovascular Medicine Section, Department of Medicine, Boston University Medical Center, MA (J.E.H., D.L.); Formerly of BG Medicine, Inc, Waltham, MA (P.M.); Department of Mathematics and Statistics, Boston University, MA (M.G.L.); Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (S.C.); and Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University, Nashville, TN (T.J.W.). levyd@nih.gov.
Boston University · USFramingham Heart Study · USMassachusetts General Hospital · USRutgers, The State University of New Jersey · USUniversity Medical Center · USBG Medicine (United States) · US
Funding
Framingham Project/LevyZIAHL006001 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEVY, DANIEL · 2009 to 2025
$51.1MDeterminants of Leukocyte Telomere Length at BirthR01HD071180 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AVIV, ABRAHAM, FACTOR-LITVAK, PAM R · 2012 to 2016
$3.3MLeukocyte TelomerE Dynamics, Gender, Menopause, Insulin Resistance and SurvivalR01AG030678 · NIA · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI AVIV, ABRAHAM · 2009 to 2013
$2.2MTHE FRAMINGHAM HEART STUDY-N01HC25195-268025195-268025195N01HC025195 · HC · TRUSTEES OF BOSTON UNIVERSITY · PI WOLF, PHILIP A · 2002 to 2006
–Intramural NIH HHS Z99 HL999999NHLBI NIH HHS N01 HC025195NHLBI NIH HHS N01-HC-25195NIA NIH HHS R01 AG030678NIA NIH HHS R01AG030678NICHD NIH HHS R01 HD071180NICHD NIH HHS R01HD071180
Abstract
objectiveCXCL12 encodes stromal cell-derived factor 1α (SDF-1), which binds to the receptor encoded by CXCR4. Variation at the CXCL12 locus is associated with coronary artery disease and endothelial progenitor cell numbers, whereas variation at the CXCR4 locus is associated with leukocyte telomere length, which has been shown to be associated with coronary artery disease. Therefore, we examined the relationships of plasma SDF-1 levels to cardiovascular disease (CVD)-related outcomes, risk factors, leukocyte telomere length, and endothelial progenitor cells. APPROACH AND
resultsSDF-1 was measured in 3359 Framingham Heart Study participants. We used Cox regression to examine relationships of SDF-1 to new-onset CVD, myocardial infarction, heart failure, and all-cause mortality; we used linear regression to evaluate associations of SDF-1 with risk factors, leukocyte telomere length, and CD34+ cell phenotypes. In multivariable models, higher SDF-1 levels were associated with older age, lower levels of high-density lipoprotein-cholesterol and cigarette smoking. Higher SDF-1 levels were associated with lower CD34+ cell frequency (P=0.02) but not with leukocyte telomere length. During follow-up (median, 9.3 years), there were 263 new-onset CVD events, 160 myocardial infarctions, 200 heart failure events, and 385 deaths. After adjusting for clinical risk factors, SDF-1 levels were associated with heart failure (P=0.04) and all-cause mortality (P=0.003) but not with CVD (P=0.39) or myocardial infarction (P=0.10). The association of SDF-1 levels with myocardial infarction was attenuated after adjustment for high-density lipoprotein-cholesterol.
conclusionsAfter adjusting for traditional CVD risk factors, SDF-1 is associated with heart failure and all-cause mortality risk. Additional studies are needed to determine whether measurement of SDF-1 levels has clinical use.
Indexed as
BiomarkersBlood PressureChemokine CXCL12FemaleFollow-Up StudiesHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPolymorphism, Single NucleotideProportional Hazards ModelsRisk FactorsSmokingTelomere HomeostasisBiomarkersChemokine CXCL12CXCL12 protein, humancardiovascular diseaseschemokine CXCL12epidemiologyheart failuremortalitymyocardial infarctionstem cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.